Dr. Doug Savage has issued a stark warning about counterfeit GLP-1 weight-loss medications after regulators seized fake pens containing dangerous substitutes.
Savage, Medical Director at Leger Clinic, said that the most serious documented case involved falsified injection pens that sent users into hypoglycaemic shock and coma. “One of the most serious documented examples involves counterfeit weight-loss pens and dangerously low blood sugar,” he explained. “The MHRA has reported hospitalisations involving hypoglycaemic shock and coma after people used fake pens. It has also confirmed that some falsified products contained insulin rather than the medicine advertised. I am referring here to published safety reports, rather than a patient case from my own practice.”
The crisis is escalating as soaring prices for licensed drugs like Mounjaro push desperate users toward unregulated grey-market suppliers. Savage stressed that the danger extends far beyond unpleasant side effects. “That illustrates why this can be much more serious than an unpleasant side effect,” he said. “A person may inject an entirely different drug from the one they believe they have bought.”
The counterfeit trade has found fertile ground on social media, where influencers market experimental compounds to bodybuilding communities and weight-loss seekers alike. Retatrutide, nicknamed “reta” or promoted as “Godzilla,” has become particularly prominent despite lacking approval from the MHRA or any regulator worldwide. The unapproved peptide is pitched as a “fat-loss peptide” or “cutting” aid, though it remains in clinical studies.
Savage outlined the dual threat facing buyers. “There are two separate concerns: the risks of the medicine itself and the additional uncertainty about the product being supplied,” he noted. Even legitimate GLP-1 medications carry serious risks requiring proper medical oversight. “Even licensed GLP-1 medicines require appropriate prescribing. They can cause side effects, and the MHRA has strengthened warnings about acute pancreatitis, including rare severe and fatal cases,” he added.
The physician urged immediate emergency care for specific symptoms. “Severe, persistent abdominal pain, particularly if it spreads to the back, needs urgent medical attention,” he said.
Unregulated products compound every known risk with unknown variables. “With an unregulated product, you may also receive the wrong ingredient, an unreliable concentration or a contaminated injection,” Savage continued. “That creates risks of dosing errors and harm unrelated to the genuine medicine. Professional-looking packaging does not establish what is inside.”
The MHRA’s recent seizures of counterfeit retatrutide and tirzepatide pens underscore how sophisticated the fake operations have become. Savage’s prescription is uncompromising: qualified medical assessment, valid prescriptions, and registered pharmacy dispensing remain the only safe pathway. “The safer route is an assessment by a qualified healthcare professional and, where appropriate, a licensed medicine dispensed by a registered pharmacy against a valid prescription,” he stated.
The broader counterfeit pharmaceutical market has exploded as demand for GLP-1 drugs outpaces supply and affordability, with social media platforms serving as the primary marketplace for these dangerous substitutions.